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Abstract
Acute asthma exacerbations are one of the most frequent reasons to visit the emergency department 
or general practitioner. Although current standard treatments for acute asthma – including supple-
mental oxygen, short-acting β2-agonists, systemic corticosteroids and anticholinergics – are quite 
effective in most patients, they are inadequate for rapid and sustained improvement in a significant 
proportion. The antileukotrienes, a relatively new class of drugs, have a role in the treatment of chro-
nic asthma. Their relatively rapid onset of action after endovenous or oral administration and their 
additive effect to β2-agonists led to the hypothesis that they might be of benefit in acute asthma. This 
review examines the efficacy of antileukotrienes in the treatment of acute asthma.
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Introduction
Antileukotrienes are a relative new class of drugs for the treatment of asthma that either block leuko-
triene synthesis or antagonize the most relevant of their receptors (Figure 1). They include:
 • 5-lipoxygenase (5-LO) inhibitors: zileuton;
 • leukotrienes receptor antagonists (LTRAs) or cysteinyl leukotriene-1 (CysLT1) antagonists: monte-
lukast, zafirlukast, and pranlukast. 
Antileukotrienes have an established role in 
the management of chronic asthma [1-3]. Se-
veral studies in adults and children have re-
ported increased levels of leukotrienes (LTs) in 
acute asthma that fall as the attack resolves [4]. 
The administration of a single dose of LTRAs 
causes a mild but significant bronchodilation 
in stable asthmatic patients, and this effect 
is additive with the bronchodilator effect of 
short-acting β2-agonists [5]. The effect can be 
observed in less than 1 hour and persists up 
to 12-24 hours [6]. These studies have led to 
speculation that LTs have a significant role in 
the bronchospasm typical of an acute asthma 
attack. However there are few studies on the 
effect of antileukotrienes in acute asthma. This 
review aims at examining the effects of these 
drugs in acute asthma. 
Role of leukotrienes  
in acute asthma
LTs, including cysteinil-LTs (LTC4, LTD4 and LTE4) and LTB4, are potent biological lipid mediators 
derived from arachidonic acid through the 5-lipoxygenase (5-LO) pathway (Figure 2) [7]. They produ-
ce bronchospasm, increase the degree of bronchial hyperresponsiveness, mucus production, and mu-
cosal edema, and stimulate airway smooth muscle cell proliferation and eosinophil recruitment in the 
airways [6]. Specific pathways for the synthesis of cysteinil-LTs are present in several types of inflam-
matory cells and become activated during allergic airway inflammation [8]. Two subtypes of receptor 
for cysteinil-LTs (CysLT1 and CysLT2) have been identified [9]. Most of the effects of cysteinil-LTs re-
levant to the pathophysiology of asthma are mediated by activation of the CysLT1 receptor, which is 
expressed in different types of inflammatory and structural cells in the airways [8]. Increased amounts 
of cysteinil-LTs are found in the blood, sputum, and urine of asthmatic patients [10]. Cysteinil-LTs are 
the most potent endogenous bronchocostrictors, increase mucus secretion in isolated animal and hu-
man airways and increase microvascular permeability in the lungs in experimental animal models [11]. 
Cysteinil-LTs have the eosinophil chemotactic effect, but the mechanisms are not completely known 
[12]. Two LTB4 receptor subtypes have been identified: BLT1 and BLT2. LTB4 is a potent chemoattrac-
tant for neutrophils and might be functionally involved in asthma exacerbations. LTB4 may contribute 
to a reduction in airway calibre due to local edema and increasing secretion, although it has no bron-
choconstrictor effect in healthy and asthmatic subjects [11,12].
Figure 1. Mechanism of action of 
antileukotrienes Figure 2. Transformations pathways of arachidonic acid and biological effects of leukotrienes and 
their receptors
5-LO = 5-lipoxygenase; COX = cyclooxygenase; FLAP = five lipoxygenase activating protein; LT = leukotrienes; 
PG = prostaglandins; SRS-A = slow reacting substance of anaphylaxis; TX = thromboxane 
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Acute asthma exacerbation
An acute asthma exacerbation can be generally defined as acute or subacute episodes of progressively 
worsening shortness of breath, cough, wheezing, and chest tightness or some combination of these 
symptoms [2]. Treatment goals for acute asthma include correction of significant hypoxemia, rapid 
reversal of airflow obstruction, and reduction in the likelihood of recurrent severe airflow obstruction 
[1,2]. Oxygen, short-acting β2-agonists, and systemic corticosteroids are the basis of management of 
acute asthma exacerbation. Treatment should be tailored to the severity of the exacerbations [1-3,13]. 
However, up to 30% of patients who present with acute asthma will fail to respond adequately to short-
acting β2-agonists [14] and benefit from systemic corticosteroids is not generally observed for 4-6 
hours or longer [15]. Therefore there is a need for new treatment options that provide benefits beyond 
the current standard treatments. 
The potential benefits of antileukotrienes in acute asthma 
Antileukotrienes provide benefit in asthma by decreasing airway inflammation and reversing broncho-
costriction [12]. Dockhorn et al. compared the effect of intravenous and oral administration of LTRA 
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montelukast on airway function. Their results showed that LTRA montelukast improved pulmonary 
function in chronic asthma. They also found that intravenous montelukast had a rapid onset of action 
and duration of action of about 24 hour in 51 patients with mild to moderate chronic asthma [16]. 
An early study by Hui et al. showed that the improvement in forced expiratory volume in one second 
(FEV1) was apparent even in those patients treated with inhaled corticosteroids [5]. 
While the role of antileukotrienes in the treatment of chronic asthma has been established by many 
trials, there are few studies of the efficacy of these drugs in acute asthma.
Leukotriene pathways are activated in acute asthma, as shown by elevations in urinary leukotriene 
excretion [4]. Given the increased production of LTs during an acute asthma exacerbation, it seems 
logical that antileukotrienes might be particularly effective in this disease. A small number of studies 
have now been performed to determine if two LTRAs, montelukast and zafirlukast, are effective in the 
treatment acute asthma. Findings of these studies are summarized in Table I.
Author, 
year 
[reference]
Antileukotriene
Baseline Maximum increase
Discharge  
from the ED 
Reduction in 
need for other 
medicationFEV1 PEFR 
FEV1(%)  
vs. placebo
PEFR (%)
Camargo, 
2003 [17]
Montelukast 
pooled 
(7 or 14 mg iv)
44,8 ± 
15.7%
14.8% vs. 
3.6%
Reduced tre-
atment failures 
vs. placebo 
(11.1% vs. 
18.2%)
Camargo, 
2010 [18]
Montelukast 
7 mg iv)
36.7 ± 
14.7%
∆FEV1  
(0-60) 21,4% 
vs. 13,0%
No significant 
vs. placebo
Silverman, 
2004 [19]
Zafirlukast 
160 mg
38.0 ± 
13.8%
At 90 min 
FEV1 in Z160 
were 64% 
predicted vs. 
61% predicted 
in placebo
Reduced the 
absolute ratio 
extended care 
by 5.1%
Zafirlukast 
20 mg once 
daily in ED 
and bid after 
discharge 
35.7 ± 
13.4%
No significant 
vs. placebo
No significantly 
reduced the 
absolute ratio 
extended care 
vs. placebo
Reduced the 
absolute ratio of 
relapse (after 28 
days) by 5.3% 
vs. placebo
Cylly, 2003 
[20]
Montelukast 
10 mg
55.4 ± 
13.9%
194,7 ± 
40.5 l/min
No significant in 
montelukast + 
prednisone vs. 
prednisone alone 
42 vs. 39.9%
Reduced in 
montelukast 
+ prednisone 
vs. prednisone 
alone
Naqvi, 
2011 [21]
Montelukast 
10 mg
178.87 ± 
27.62 l/min
194,46 ± 
33,46 l/min  
(p = 0.05)
Table I. Clinical studies on montelukast and zafirlukast in acute asthma
ED = emergency department
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Clinical studies
In 2003 Camargo et al. in a randomized, double blind, parallel-group study in 201 adults with moderate 
to severe asthma (FEV1 ≤ 70% of the predicted) evaluated the response to intravenous montelukast 
(7 mg or 14 mg) as adjunctive therapy for acute asthma [17]. Primary endpoint of the study was the 
average percentage change in FEV1 from preallocation baseline at 20 minutes after study medication 
infusion. There was no difference in treatment effect between the groups receiving montelukast 7 or 
14 mg. Compared with the group receiving standard therapy plus placebo, a significant improvement 
in FEV1 was observed among patients receiving standard therapy plus intravenous montelukast and 
this benefit was maintained for at least 2 hours. The mean percentage at 20 minutes was 14.8% versus 
3.6% for the pooled montelukast and placebo treatment groups respectively. These values were 19.5% 
and 5.2% respectively, over the first 60 minutes [17]. 
In another study Camargo et al. evaluated the efficacy of intravenous montelukast as adjunctive the-
rapy for acute asthma [18]. A total of 583 adults with acute asthma with FEV1 ≤ 50% predicted were 
randomly allocated to intravenous montelukast 7 mg (n = 291) or placebo (n = 292) in addition to 
standard care. The primary efficacy endpoint was the time-weighted average change in FEV1 during 60 
minutes after drug administration. The median time-weighted percent change in FEV1 from prealloca-
tion baseline during the first 60 minutes after administration were 21.4% and 13.0% in the montelukast 
group and placebo group respectively. The percentage of patients with treatment failure was slightly 
lower in the montelukast group (26,8%) than in the placebo one (29,9%), but this difference was not 
statistically significant (OR = 0.92; 95% CI 0.63-1.34) [18]. 
Silverman et al., in a randomized, double-blind, multicenter study, evaluated the adding of therapy 
with zafirlukast to standardized care for patients with acute asthma in the Emergency Department 
(ED). A total of 641 patients presenting to the ED with acute asthma were randomized to receive either 
single-dose zafirlukast 160 mg, zafirlukast 20 mg, or placebo. Patients who were discharged from ED 
after 4 h continued outpatient therapy over a 28-day period and received either zafirlukast 20 mg bid or 
placebo in addition to prednisone. The primary endpoint was the effect of zafirlukast on relapse after 
ED discharge. Other assestements were the rate of extended care (ED stay > 4 h or hospitalization) and 
FEV1. At the end of the ED period, 14% of all patients required extend care as follows: 9.9% treated 
with zafirlukast 160 mg, 16.5% treated with zafirlukast 20 mg, and 15% treated with placebo. Compa-
red with placebo, zafirlukast 160 mg reduced the absolute rate of extended care by 5.1% (p = 0.052). 
Treatment with zafirlukast 160 mg (but not with zafirlukast 20 mg) showed a stastistically significant 
effect, compared with placebo, in improving FEV1 at 90 minutes (p = 0.02) and at 210 minutes (p = 
0.04). Compared with placebo, treatment with zafirlukast 20 mg bid reduced the absolute rate of relapse 
by 5.3% and, among patients who relapsed, the hospitalization rate was 6.2% for zafirlukast treated-
patients and 10.3% for placebo-treated patients [19]. 
Cylly et al. compared the effects on peak expiratory flow rate (PEFR) of oral montelukast added to in-
travenous steroid, intravenous steroid alone and placebo during the 24 hours following administration 
[20]. Secondary endpoints were Borg dyspnoea score and use of rescue medication. Seventy asthmatic 
patients (FEV1 = 40-80% predicted) were enrolled and randomized to receive montelukast (10 mg) 
plus intravenous prednisolone (1 mg/ml), intravenous prednisolone alone (1 mg/kg) or placebo. Com-
pared with placebo, the montelukast + prednisolone group and the prednisolone alone group had si-
gnificant percentage change from baseline in PEFR in the entire 24 hours period (10.3, 42, 39.9%) but 
the difference in PEFR between montelukast plus prednisolone and prednisolone alone did not reach 
statistical significance. Furthermore, montelukast plus prednisolone group require less inhaled short-
acting β2-agonist than other two groups [20]. 
Naqvi et al. conducted a comparative prospective study in 100 adult asthmatic patients randomized 
in two groups [21]. Group A was considered as control and was treated with conventional therapy 
(oxygen, short-acting β2-agonists, corticosteroids and methylxantine). In group B, along with conven-
80 Reviews in Health Care 2012; 3(2) © SEEd All rights reserved
Role of antileukotrienes in acute asthma exacerbations
tional therapy, montelukast 10  mg was added on daily basis. All the parameters of the study were 
recorded at the time of admission then after 24 h, 48, h, 72 h, first week, second week and fourth week 
respectively. In group B, PEFR after 48 h was significantly improved (p = 0.05) compared with group A. 
In comparation of force expiratory volume % (FEV1 predicted) between group A and group B, after 24 
h significant change was noticed in group B (p = 0.05), but, after 48 h, there was no significant different 
noticed in both groups (p = 0.07) [21]. 
Conclusions
The role of antileukotrienes in the treatment of acute asthma is still unknown. In a previous review 
Kluitert and Watson underlined that there are few studies evaluating the effect of an LTRA in acute 
asthma and these studies are limited by the lack of clinically relevant outcomes such as hospitalization 
and relapse rates. However, the study on zafirlukast, in which patients were treated both acutely and on 
discharge from the ED, demonstrated a reduction in the number of patients requiring a longer stay in 
ED and/or hospitalization, a lower relapse rate and greater improvement in lung function [19,22]. In 
their randomized, double-blind, placebo-controlled study, published in 2010, Camargo et al. found 
that intravenous montelukast, when added to standard therapy, provided significant, rapid (onset of 
action at 10 minutes), and sustained (throughout the 2 hours) benefit in acute asthma, as indicated by 
relief of airway obstruction [18]. Another study showed that adding oral montelukast to intravenous 
steroid caused significant change from baseline in PEFR in the entire 24 hours and required less inha-
led short-acting β2-agonist as a rescue medication [20]. In all studies antileukotrienes were found to be 
generally safe and well tolerated in acute asthma. In summary, although only few studies have been 
performed yet, there are data suggesting that potential advantages of prescribing antileukotrienes as 
adjunctive therapy in acute asthma. Oral or in-
travenous LTRAs have an additive benefit in 
terms of early improvement in lung function 
(FEV1 and PEFR), reduce the necessity of 
extended care in ED, relapses rate after dischar-
ge and rescue medication with short acting β2-
agonist. However, additional studies are neces-
sary to determine the potential additive benefit 
of antileukotrienes to current acute asthma tre-
atment. 
Questions for further research
There are still few studies on the role of anti-
leukotrienes in the treatment of acute asth-
ma. Additional studies with clinically rele-
vant outcomes (i.e., hospitalization and re-
lapse rate) should be performed in order to 
determine their potential additive benefit to 
current acute asthma treatment.
The review in brief
Clinical question Defining the role of antileukotrienes in acute asthma
Type of review Narrative
Search of the 
literature
Medline search for English-language articles using the following keywords: asthma, leukotrienes, 
cysteinil-leukotrienes, airways inflammation
Conclusions Data suggest potential advantages of antileukotrienes prescription as adjunctive therapy in acute 
asthma. Oral or intravenous LTRAs have an additive benefit in terms of early improvement in lung 
function (FEV1 and PEFR), reduce the necessity of extended care in ED, relapses rate after discharge 
and rescue medication with short acting β2-agonist 
Limitations Only few clinical trials have been performed, thus this review is based on a limited number of studies
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